Company news

Taysha Gene Therapies, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 4, 2024

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

November 28, 2023

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

November 13, 2023

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

November 6, 2023

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

October 23, 2023

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

October 9, 2023

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

September 25, 2023

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

September 18, 2023

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

August 23, 2023

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

August 13, 2023

Taysha Gene Therapies Announces $150 Million Private Placement Financing

August 13, 2023

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

July 30, 2023

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

June 27, 2023

Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome

June 14, 2023

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

June 4, 2023

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 18, 2023

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

May 3, 2023

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

April 26, 2023

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 27, 2023

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28

March 14, 2023

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook

January 30, 2023

Taysha Gene Therapies Announces Executive Leadership Changes

December 15, 2022

Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit

November 28, 2022

Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8

November 1, 2022

Taysha Announces Pricing of Public Offering of Common Stock

October 25, 2022

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock

October 24, 2022

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs

October 23, 2022

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

October 23, 2022

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs

October 23, 2022

Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)

October 5, 2022

Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

August 8, 2022

Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

July 31, 2022

Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022

July 5, 2022

Taysha Gene Therapies Announces Annual Stockholder Meeting

June 12, 2022

Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention

June 1, 2022

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 15, 2022

Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

May 10, 2022

Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy

May 9, 2022

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)

May 2, 2022

Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit

April 24, 2022

Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

April 17, 2022

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 30, 2022

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

March 28, 2022

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

March 23, 2022

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

March 22, 2022

Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference

March 7, 2022

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium

February 8, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.